Statistically significant differences in currently untargetable genomic alterations included higher frequencies of TP53 (70% vs. 63%, p < 0.0001) and RB1 inactivation (10% vs. 2%, p < 0.0001) in MTAP‐intact compared to MTAP‐lost NSCLC. This evidence concerns the gene TP53 and non-small cell lung carcinoma.